Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580] Technology ...
Benralizumab for previously treated severe nasal polyps [ID1659] Technology appraisal guidance TBC Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback